STOCK TITAN

[6-K] Cardiol Therapeutics Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Lockheed Martin Corporation (LMT) filed a Form 8-K on July 22 2025 to furnish its second-quarter 2025 earnings release.

  • Item 2.02 – Results of Operations and Financial Condition: The company issued a news release on the same date covering results for the quarter ended June 29 2025. The release is attached as Exhibit 99.1 and is furnished, not filed, under the Exchange Act.
  • Item 9.01 – Financial Statements and Exhibits: Exhibits include 99.1 (earnings press release) and 104 (cover-page Inline XBRL).

The 8-K contains no quantitative financial metrics, outlook, or strategic commentary; investors must refer to Exhibit 99.1 for detailed results.

La Lockheed Martin Corporation (LMT) ha presentato un modulo 8-K il 22 luglio 2025 per fornire il comunicato sui risultati del secondo trimestre 2025.

  • Voce 2.02 – Risultati Operativi e Condizione Finanziaria: La società ha diffuso un comunicato stampa nella stessa data riguardante i risultati del trimestre terminato il 29 giugno 2025. Il comunicato è allegato come Exhibits 99.1 ed è fornito, non depositato, ai sensi dell'Exchange Act.
  • Voce 9.01 – Bilanci e Allegati: Gli allegati includono 99.1 (comunicato stampa sui risultati) e 104 (pagina di copertina Inline XBRL).

Il modulo 8-K non contiene dati finanziari quantitativi, previsioni o commenti strategici; gli investitori devono consultare l'Exhibit 99.1 per i risultati dettagliati.

Lockheed Martin Corporation (LMT) presentó un Formulario 8-K el 22 de julio de 2025 para proporcionar su comunicado de resultados del segundo trimestre de 2025.

  • Artículo 2.02 – Resultados de Operaciones y Condición Financiera: La compañía emitió un comunicado de prensa en la misma fecha con los resultados del trimestre finalizado el 29 de junio de 2025. El comunicado está adjunto como Exhibit 99.1 y se proporciona, no se presenta, bajo la Exchange Act.
  • Artículo 9.01 – Estados Financieros y Anexos: Los anexos incluyen 99.1 (comunicado de resultados) y 104 (portada Inline XBRL).

El 8-K no contiene métricas financieras cuantitativas, perspectivas ni comentarios estratégicos; los inversores deben consultar el Exhibit 99.1 para obtener resultados detallados.

록히드 마틴 코퍼레이션(LMT)은 2025년 7월 22일 2025년 2분기 실적 발표를 제공하기 위해 Form 8-K를 제출했습니다.

  • 항목 2.02 – 운영 결과 및 재무 상태: 회사는 2025년 6월 29일 종료된 분기 실적을 같은 날 보도자료로 발표했습니다. 해당 보도자료는 Exhibit 99.1로 첨부되었으며, Exchange Act에 따라 제출된 것이 아니라 제공된 것입니다.
  • 항목 9.01 – 재무제표 및 전시자료: 전시자료에는 99.1(실적 보도자료)과 104(표지 Inline XBRL)가 포함되어 있습니다.

8-K에는 정량적 재무 지표, 전망 또는 전략적 논평이 포함되어 있지 않으며, 투자자들은 자세한 결과를 위해 Exhibit 99.1을 참조해야 합니다.

Lockheed Martin Corporation (LMT) a déposé un formulaire 8-K le 22 juillet 2025 afin de fournir son communiqué de résultats pour le deuxième trimestre 2025.

  • Point 2.02 – Résultats d'exploitation et situation financière : La société a publié un communiqué de presse à la même date couvrant les résultats du trimestre clos le 29 juin 2025. Le communiqué est joint en tant qu'Exhibit 99.1 et est fourni, non déposé, conformément à la Exchange Act.
  • Point 9.01 – États financiers et annexes : Les annexes comprennent 99.1 (communiqué de résultats) et 104 (page de couverture Inline XBRL).

Le formulaire 8-K ne contient pas de données financières quantitatives, de perspectives ou de commentaires stratégiques ; les investisseurs doivent se référer à l'Exhibit 99.1 pour des résultats détaillés.

Die Lockheed Martin Corporation (LMT) reichte am 22. Juli 2025 ein Formular 8-K ein, um ihre Ergebnisveröffentlichung für das zweite Quartal 2025 bereitzustellen.

  • Punkt 2.02 – Betriebsergebnisse und Finanzlage: Das Unternehmen veröffentlichte am selben Tag eine Pressemitteilung zu den Ergebnissen für das Quartal, das am 29. Juni 2025 endete. Die Mitteilung ist als Exhibit 99.1 beigefügt und wird gemäß dem Exchange Act bereitgestellt, nicht eingereicht.
  • Punkt 9.01 – Finanzberichte und Anhänge: Die Anhänge umfassen 99.1 (Ergebnis-Pressemitteilung) und 104 (Deckblatt Inline XBRL).

Das 8-K enthält keine quantitativen Finanzkennzahlen, Prognosen oder strategische Kommentare; Anleger müssen Exhibit 99.1 für detaillierte Ergebnisse konsultieren.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine 8-K furnishes Q2 2025 earnings release; no numbers disclosed here—neutral informational filing.

This Form 8-K is procedural. By furnishing, not filing, the press release, Lockheed Martin avoids Section 18 liability while giving investors a single reference point for its Q2 2025 results. Because the document omits revenue, EPS, or guidance, it offers no basis to re-evaluate valuation or risk. Impact on the share price will depend entirely on data contained in Exhibit 99.1, not in this filing. I classify the disclosure as neutral and non-impactful until the underlying figures are reviewed.

La Lockheed Martin Corporation (LMT) ha presentato un modulo 8-K il 22 luglio 2025 per fornire il comunicato sui risultati del secondo trimestre 2025.

  • Voce 2.02 – Risultati Operativi e Condizione Finanziaria: La società ha diffuso un comunicato stampa nella stessa data riguardante i risultati del trimestre terminato il 29 giugno 2025. Il comunicato è allegato come Exhibits 99.1 ed è fornito, non depositato, ai sensi dell'Exchange Act.
  • Voce 9.01 – Bilanci e Allegati: Gli allegati includono 99.1 (comunicato stampa sui risultati) e 104 (pagina di copertina Inline XBRL).

Il modulo 8-K non contiene dati finanziari quantitativi, previsioni o commenti strategici; gli investitori devono consultare l'Exhibit 99.1 per i risultati dettagliati.

Lockheed Martin Corporation (LMT) presentó un Formulario 8-K el 22 de julio de 2025 para proporcionar su comunicado de resultados del segundo trimestre de 2025.

  • Artículo 2.02 – Resultados de Operaciones y Condición Financiera: La compañía emitió un comunicado de prensa en la misma fecha con los resultados del trimestre finalizado el 29 de junio de 2025. El comunicado está adjunto como Exhibit 99.1 y se proporciona, no se presenta, bajo la Exchange Act.
  • Artículo 9.01 – Estados Financieros y Anexos: Los anexos incluyen 99.1 (comunicado de resultados) y 104 (portada Inline XBRL).

El 8-K no contiene métricas financieras cuantitativas, perspectivas ni comentarios estratégicos; los inversores deben consultar el Exhibit 99.1 para obtener resultados detallados.

록히드 마틴 코퍼레이션(LMT)은 2025년 7월 22일 2025년 2분기 실적 발표를 제공하기 위해 Form 8-K를 제출했습니다.

  • 항목 2.02 – 운영 결과 및 재무 상태: 회사는 2025년 6월 29일 종료된 분기 실적을 같은 날 보도자료로 발표했습니다. 해당 보도자료는 Exhibit 99.1로 첨부되었으며, Exchange Act에 따라 제출된 것이 아니라 제공된 것입니다.
  • 항목 9.01 – 재무제표 및 전시자료: 전시자료에는 99.1(실적 보도자료)과 104(표지 Inline XBRL)가 포함되어 있습니다.

8-K에는 정량적 재무 지표, 전망 또는 전략적 논평이 포함되어 있지 않으며, 투자자들은 자세한 결과를 위해 Exhibit 99.1을 참조해야 합니다.

Lockheed Martin Corporation (LMT) a déposé un formulaire 8-K le 22 juillet 2025 afin de fournir son communiqué de résultats pour le deuxième trimestre 2025.

  • Point 2.02 – Résultats d'exploitation et situation financière : La société a publié un communiqué de presse à la même date couvrant les résultats du trimestre clos le 29 juin 2025. Le communiqué est joint en tant qu'Exhibit 99.1 et est fourni, non déposé, conformément à la Exchange Act.
  • Point 9.01 – États financiers et annexes : Les annexes comprennent 99.1 (communiqué de résultats) et 104 (page de couverture Inline XBRL).

Le formulaire 8-K ne contient pas de données financières quantitatives, de perspectives ou de commentaires stratégiques ; les investisseurs doivent se référer à l'Exhibit 99.1 pour des résultats détaillés.

Die Lockheed Martin Corporation (LMT) reichte am 22. Juli 2025 ein Formular 8-K ein, um ihre Ergebnisveröffentlichung für das zweite Quartal 2025 bereitzustellen.

  • Punkt 2.02 – Betriebsergebnisse und Finanzlage: Das Unternehmen veröffentlichte am selben Tag eine Pressemitteilung zu den Ergebnissen für das Quartal, das am 29. Juni 2025 endete. Die Mitteilung ist als Exhibit 99.1 beigefügt und wird gemäß dem Exchange Act bereitgestellt, nicht eingereicht.
  • Punkt 9.01 – Finanzberichte und Anhänge: Die Anhänge umfassen 99.1 (Ergebnis-Pressemitteilung) und 104 (Deckblatt Inline XBRL).

Das 8-K enthält keine quantitativen Finanzkennzahlen, Prognosen oder strategische Kommentare; Anleger müssen Exhibit 99.1 für detaillierte Ergebnisse konsultieren.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F


SUBMITTED HEREWITH

Exhibits

Exhibit   Description
   
99.1   News Release dated July 22, 2025 - Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx™ in Acute Myocarditis


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  CARDIOL THERAPEUTICS INC.
  (Registrant)
     
Date: July 22, 2025 By: /s/ Chris Waddick
   
    Chris Waddick
  Title: Chief Financial Officer


FAQ

Why did Lockheed Martin (LMT) file this Form 8-K on July 22 2025?

To furnish its Q2 2025 earnings news release as Exhibit 99.1 under Item 2.02 and Item 9.01.

Does the 8-K include Lockheed Martin’s Q2 2025 revenue or EPS figures?

No. The filing itself contains no quantitative results; investors must read Exhibit 99.1 for details.

What exhibits accompany Lockheed Martin’s July 22 2025 8-K?

99.1: Earnings press release for quarter ended June 29 2025; 104: Cover Page Inline XBRL file.

Is the earnings release considered “filed” with the SEC?

No. It is expressly stated as “furnished” under Item 2.02, limiting certain liabilities under the Exchange Act.
Cardiol Therapeu

NASDAQ:CRDL

CRDL Rankings

CRDL Latest News

CRDL Stock Data

109.92M
78.75M
4%
12.19%
2.29%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Oakville